Published in final edited form as:

Cardiovasc Intervent Radiol. 2019 September ; 42(9): 1240–1254. doi:10.1007/s00270-019-02284-9.

Liver-Directed therapies for colorectal cancer liver metastases

Nancy Kemeny^{1,*}, Ieva Kurilova^{2,*}, Jia Li^{1,*}, Juan C. Camacho³, Constantinos T. Sofocleous^{3,§}

¹Medical Oncology, Department of Medicine, MSKCC, 1275 York Avenue, New York, NY

²Department of Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands. GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.

³Interventional Radiology, Department of Radiology, MSKCC, 1275 York Avenue, New York, NY

Concise and informative title:

role of liver-directed chemotherapy and loco-regional interventions in managing colorectal cancer liver metastases

Keywords

hepatic arterial pump therapy; systemic chemotherapy; loco-regional therapy

1. Epidemiology, predisposing factor and pathology

Colorectal cancer (CRC) is the third most common cancer worldwide, resulting in an estimated 140,250 new cases and 50,630 deaths in 2018 [1, 2]. Liver is the most common visceral metastatic site due to the portal venous drainage from the colon. About 15% of patients present with synchronous liver metastases at initial diagnosis, which is an

Terms of use and reuse: academic research for non-commercial purposes, see here for full terms. <https://www.springer.com/aam-terms-v1>

[§]**corresponding author** Constantinos T. Sofocleous, MD, PhD, FSIR, FCIRSE, Professor of Interventional Radiology Weill-Cornell Medical College, Attending Physician Interventional Oncology, Memorial Sloan Kettering Cancer Center, Phone: 212-639-3379, Fax: 212-717-3325, sofoclec@mskcc.org.

^{*}Joint first authorship

²Conflict of interest (COI)

Authors Jia Li, Ieva Kurilova, Juan C Camacho declare that they have no conflict of interest.

Nancy Kemeny received research fund from Amgen

Constantinos T. Sofocleous declare Research Support: Ethicon J&J, BTG, Consultant/Advisory Board: Terumo, Ethicon J&J, GE.

³Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

⁴Informed consent

For this type of study informed consent is not required

⁵Consent for publication

Consent for publication was obtained for every individual person's data included in the study

Publisher's Disclaimer: This Author Accepted Manuscript is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication but has not been copyedited or corrected. The official version of record that is published in the journal is kept up to date and so may therefore differ from this version.

independent poor prognostic factor [3]. Approximately 50% of patients ultimately develop liver metastasis during the course of the disease.

The risk factors for CRC are classified to *non-modifiable* (age, family history, hereditary predisposition, inflammatory bowel disease and adenomatous polyp) and *modifiable* (diets, smoking, obesity and high alcohol consumption)[4].

Left-sided and right-sided CRCs harbor different clinical and biologic characteristics with different exposures to potential carcinogenic toxins and microbiota, which can potentially impact the prognosis. Right-sided primary CRCs are more likely to have genome-wide hypermethylation via the CpG island methylator phenotype (CIMP), hypermutated state via microsatellite instability, *BRAF* mutation [5], greater proportions of the "microsatellite unstable/immune" CMS1 and the "metabolic" CMS3 consensus molecular subtypes. Molecular tumor subtypes (different from primary tumor) have been defined for colorectal liver metastases (CLM) [6] and impact prognosis.

KRAS mutation is detected in 35-45% of CRCs and it is a strong negative *prognostic* biomarker (associated with more infiltrating/migratory characteristics of cancer cells [7]) and a negative *predictive* biomarker in terms of resistance to anti-EGFR treatment [8], higher incidence of positive and narrow margins at surgery [9] and worse oncologic outcomes after ablation of CLM [10, 11]. BRAF-mutant cancers, comprising 10% of all CRCs, represent a distinct subset of CRC with its own clinical implications with regard to prognosis, treatments and emerging therapeutic strategies. BRAF-mutant CRCs tend to be microsatellite instable (MSI-high), mucinous histology, poorly differentiated, less likely to have metastatic disease amenable for surgical resection as well as poorer overall survival (OS) [12]. Approximately, 15-20 % of colorectal cancers display MSI with prognostic and therapeutic implications as these tumors are highly immunogenic and can be targeted with immunotherapy [13].

Main limitation of the studies, analyzing outcomes of CLM include heterogeneity in terms of prior therapies (treatment-naïve, patients after first-, second-, or subsequent treatment lines) and tumor subtypes.

Summary of the most important facts about liver-directed and systemic therapies for CLM is presented in Table 1.

2. Diagnosis and initial work-up

Most primary CRCs are diagnosed through colonoscopy either through regular screening or due to symptoms such as change in bowel habits, GI bleeding (hematochezia, melena, occult blood loss, iron deficiency anemia) or abdominal pain. Some cases are diagnosed due to signs or symptoms caused by metastatic disease.

CRCs can spread by lymphatic and hematogenous dissemination, as well as contiguous and transperitoneal spread. The most common metastatic sites are regional lymph nodes, liver, lung and bones.

This article reviews management of CLM. The only potentially curative treatment option for CLM is surgical resection and/or complete ablation [14]. Recent advances in chemotherapy, surgical and interventional techniques allow a subset of initially unresectable CLMs to be downsized to resection or ablation. Thus precise assessment of the extent of disease is critical to determine the resectability. Several imaging modalities are used to identify CLM. Commonly used imaging modalities are ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), ^{18}F -FDG PET/CT and more recently fully integrated ^{18}F -FDG PET/MR. The utility of different imaging modalities is described in Table 2.

Our recommendation of working up CLMs is to start with CT chest/abdomen/pelvis with triphasic liver protocol. If the patient is potentially resectable, liver MRI should be the next step to further define the extent of disease to ensure a proper selection for surgery. ^{18}F -FDG PET/CT is also advisable especially prior to resection or ablation of metastatic disease [15].

3. Approved/recommended treatments

Liver resection is considered to be a “golden standard” for CLM treatment, with median OS in liver resected patients of 28-46 months [16]. However, only 15%-20% of the patients are considered to be eligible for liver surgery [17, 18]. Patients with oligometastatic disease (OMD), located in anatomically favorable territory and low tumor burden may be considered to have upfront liver metastatectomy, followed by 6-months adjuvant therapy. National Comprehensive Cancer Network (NCCN) guidelines recommend surgery or ablation alone or in combination as long as all visible metastases can be eradicated [15].

When liver metastases are completely resected and/or ablated, long-term survival and potential cure could be achieved. In patients who can undergo liver resection followed by adjuvant systemic therapy plus HAI, 5-year OS as high as 78% can be achieved [19], which is significantly better than 5-year OS of the patients treated with chemotherapy-alone, which is around 10%. Clinical Risk Score (CRS) and margins impact surgical outcomes and potential for cure [14, 20].

Cytotoxic chemotherapies remain the mainstream therapy for metastatic CRC, even in patients with resectable or amenable to ablation disease. Chemotherapy combined with resection or ablation of all metastatic sites significantly improve outcomes in this patient population [21].

Adjuvant therapies after CLM resection

Adjuvant therapy options following liver resection include systemic chemotherapy with FOLFOX or 5-FU/LV [22] and hepatic arterial infusion chemotherapy (HAI) with floxuridine (FUDR) alone or in combination with systemic chemotherapy in certain institutions.

HAI FUDR demonstrated liver PFS and OS benefit, based on four randomized trials in the adjuvant setting [23-26] (*please see Supplement 1 for detailed HAI data*). NCCN guidelines conclude that HAI infusion with or without systemic chemotherapy is an option as adjuvant or peri-operative therapy in the setting of liver metastatectomy. In addition to FUDR,

several other chemotherapeutic agents can be administered through HAI, including 5-FU, mitomycin, oxaliplatin and irinotecan [27-29]. However, due to the complexity of hepatic pump placement, management of HAI pump and administration of chemotherapy via HAI, this approach has only been utilized in certain institutions with relevant expertise.

Neoadjuvant conversion therapy

Among patients with CLM, up to 30% of initially unresectable patients could have disease converted to surgically resectable after receiving systemic therapy. The options of conversion therapy are as follows:

Systemic conversion therapies include the following:

1. *FOLFOX or CAPOX +/- bevacizumab*: for the patients without prior oxaliplatin exposure [30-32]. Bevacizumab has modest benefit when in combination of FOLFOX or XELOX in the peri-operative setting but with potential complications such as arterial thromboembolic events, hemorrhage, delayed wound healing, gastrointestinal perforation, biliary complications, or severe hypertension. Its use in the peri-operative setting requires caution, in general, it is recommended avoiding bevacizumab 4 weeks before and after invasive operations [32].
2. *FOLFIRI +/- cetuximab or panitumumab*: for the patients with prior oxaliplatin as adjuvant therapy, left sided primary cancer and wild-type KRAS [33-35];
3. *FOLFOXIRI +/- bevacizumab*. This regimen is generally used in younger, healthier patients; thus the patients with high tumor burden, risk of chemotherapy-related toxicity should be under consideration when choosing this regimen. This regimen was associated with conversion rate of up to 40% with significantly prolonged OS [36-39].

Locoregional therapies include the following:

1. HAI therapy alone or with systemic chemotherapy. HAI with FUDR plus systemic chemotherapy (FOLFOX, FOLFIRI) as conversion therapy resulted in CLM resectability in nearly 50% of the patients [40, 41].
2. Neoadjuvant ⁹⁰Y radiation lobectomy [42] or transarterial chemoembolization with drug-eluting beads (DEBIRI-TACE) [43].

Unresectable CLMs

If complete resection /ablation of CLM is not feasible or patients are not fit surgical candidates, other locoregional therapies, such as HAI, percutaneous ablation, chemoembolization, radioembolization (RE), and radiation therapy (RT), including stereotactic body RT (SBRT) can all be considered for the patients with OMD (see Section 4 for detailed discussion). Also, in selected patients percutaneous ablation within the “test of time” concept maybe preferable to surgery as the initial local cure while observing the disease biology in potentially resectable patients. In the event of local failure in the ablation site, in patients without multifocal progression during the follow - up period surgery remains

a subsequent option. “Test of time” allows expression of disease biology and can spare patients with an aggressive tumor biology the morbidity of a non-beneficial surgery [44]. Percutaneous ablation can also be useful for disease control without systemic chemotherapy administration in selected patients, allowing for “chemotherapy holiday”.

Systemic palliative therapies

For this category, goals of therapy focus on palliative and non-curative measures with expectation of maintaining quality of life and potentially prolonging OS. Many combinations are available, consisting of cytotoxic chemotherapeutic agents including irinotecan, oxaliplatin, capecitabine; monoclonal antibodies targeting VEGF and EGFR pathways such as bevacizumab, ramucirumab, cetuximab, panitumumab; tyrosine kinase inhibitor regorafenib, recombinant fusion protein aflibercept, and trifluridine-tipiracil, as well as immunotherapy. Overall principle is to expose patients to all active agents sequentially if they can tolerate. Enrollment in a clinical trial is always recommended in this setting.

First-line and beyond first line palliative locoregional and systemic treatment options for the patients with CLM are described in Table 3.

4. Role of interventional oncology /radiology (IO/IR)

The main focus of IO/IR in mCRC is oligometastatic disease (OMD). OMD is characterized by disease localization to a few sites and tumors allowing the option to use local and ablative treatments (LAT) aiming to improve disease control and therefore clinical outcome in these patients [45]. Although the mortality of CRC patients has dramatically decreased in the last 20 years following the introduction of new systemic treatments, the management of metastatic CRC remains a major challenge with surgical resection and ablation being the only potentially curative options.

IO/IR plays an important role in the management of mCRC from disease diagnosis through tissue sampling, treatment of unresectable OMD, bridging potentially resectable patients or treating chemorefractory metastatic disease in the salvage setting [46] to palliation. Therefore, there is a strong international consensus that the interventional oncologist/radiologist should be a standing member of the institutional tumor board [47].

Most frequent clinical scenarios for LAT include the following:

1. *Neoadjuvant setting.* In this setting LAT can be used as:
 - Potentially curative treatment for unresectable patients with limited metastatic tumor burden;
 - Induction therapy in order to downsize tumor in potentially resectable patients [43];
 - Percutaneous ablation can be applied within the “test of time” concept, when it is used instead of surgery in order to observe the disease biology in potentially resectable patients [44].

2. *Adjuvant setting.* In this setting LAT can be used for:
 - Combination with first-line chemotherapy in carefully selected patients [43, 48];
 - Treatment of CLM by means of combined percutaneous and endovascular therapies [49-53];
 - Induction of distant tumor response by combining LAT with immunotherapy;
 - Disease control without systemic chemotherapy administration in selected patients, allowing for “chemotherapy holiday”.
3. *Salvage setting:* for chemorefractory patients with a goal to improve disease control and OS with minimal impact on the quality of life [54].

Percutaneous ablative techniques

Percutaneous ablative techniques include a wide range of modalities, which are divided into two groups:

1. Thermal modalities (heat- and cold-based). They include radiofrequency (RFA) [55-60], microwave (MWA) [61-64], cryoablation [65], laser ablation [66-68] and high intensity focused ultrasound [69];
2. Non-thermal modality, which include irreversible electroporation [70-72].

RFA is the most extensively studied ablation modality with multiple larger retrospective case matched comparisons as well as meta-analyses available, comparing RFA to surgical resection or using RFA in addition to systemic chemotherapy [21, 73-78].

For treatment of CLM, hepatocellular carcinoma algorithm of the West and Japan is often applied, which recommends RFA for < 3 cm liver metastases in unresectable patients with 3 tumors [79-81]. However, for CLM the lesion number is not an absolute limiting factor for RFA, if successful treatment of all metastases can be accomplished, with most centers preferentially treating patients with 5 lesions. Several studies demonstrated highest rates of complete tumor destruction with RFA for lesions of 3 cm [82-84], with oncological outcomes similar to surgical resection [82, 85-89].

Recent thermal ablation literature focuses on improving the relatively high local tumor recurrence rates (2%-60%) [59, 63, 90-92]. This can be achieved by creating sufficient (ideally >10 mm) minimal ablation margins (“A0 ablation” concept) [63, 93], incorporating metabolic image-guidance for tumor ablation by means of ¹⁸F FDG-PET [94] as well as stratifying the patients based on modified clinical risk scores and genetic mutation profile, such as KRAS mutation [11, 59, 86, 93, 95, 96]. Essentially ablation with margins of >10 mm are associated with few if any local failures [63, 86]. Similarly ablation margins of > 5 mm with immediate post-ablation zone center and margin biopsy confirming complete tumor necrosis offered over 97% local progression-free survival 30 months post-RFA [96].

The CLOCC trial is extremely important as it the only randomized-controlled trial (RCT), providing the evidence of OS advantage when using LAT (by means of RFA) in combination with systemic chemotherapy vs. systemic chemotherapy alone, with OS at 8 years of 36% and 8%, respectively [21, 76]. However, due to trial's limitations, new multicenter prospective COLLISION trial has been initiated, comparing thermal ablation (TA) and liver resection outcomes for CLM [97]. The main hypothesis is that TA might enable to achieve similar local tumor control and OS rates to surgical resection while reducing morbidity, mortality, direct economic costs, hospitalization days and improving quality of life [97]. Achieving similar local tumor control and OS with TA compared to surgery, will further establish the terms "resectable" and "ablatable" as synonyms.

The outcomes following RFA and MWA in term of safety and toxicity are comparable. Although there is data on MWA superiority than RFA for CLM [98], when stratified by margin size there was no difference in LTPFS [63] with no LTP for tumors ablated with margins > 10 mm. The latest generation MWA systems offer technical advantages such as greater intra-tumoral temperature, deeper penetration of energy, propagation across the poorly conductive tissues, less sensitivity to the heat-sink effect, and larger ablation volume, enabling to treat larger tumors with adequate safety margin when compared to RFA [99-101].

Endovascular approaches

While ablation and resection are the only potentially curative options for mCRC, only around 20% of CLM patients are eligible for these treatments. Endovascular approaches, such as transarterial chemoembolization (TACE) [102-108] and ^{90}Y radioembolization (RE) [15, 48, 109-117] demonstrated improvement in OS and quality of life in chemorefractory CLM.

- RE— ^{90}Y RE is an FDA approved liver brachytherapy, recommended through the NCCN and the ESMO guidelines for the treatment of CLM in the salvage setting with liver disease progression while on or after second line chemotherapy with encouraging oncologic outcomes [15, 45, 48, 109, 112, 113, 118-129]. It is also used to treat unresectable non-colorectal liver metastases [130-132]. However, when the patients present to the RE in salvage setting with advanced tumor load, unfavorable biological tumor characteristics and comorbidities, the range of outcomes post-RE is highly variable, with objective response rates varying between 10%-48% when RE is applied in the third and subsequent chemotherapy regiment setting [122, 128, 133, 134].

The main effect of RE is attributed to radiation as it has a minimal embolic effect. Three types of particles are currently being used for RE: ^{90}Y microspheres (resin or glass-based) and ^{166}Ho microspheres.

^{90}Y microspheres are the most commonly used microspheres for RE. ^{90}Y is β -emitter, with 96% of radiation delivered within 12 days in the tumor, with up to 1-cm penetration depth around each microsphere, enabling to achieve treatment margins around the tumor, similarly to surgical resection or thermal ablation [135].

Physical properties of glass-based and resin microspheres are different due to the size and number of the particles required to deliver the same radiation dose. RE with resin microspheres enables to deliver higher number of microspheres with potentially more homogeneous tumor coverage with a risk of embolic effect and stasis prior to total dose delivery [109, 136, 137]. ^{90}Y microspheres are not radiopaque, making real-time infusion monitoring challenging. Modified infusion methods using diluted or undiluted contrast medium have been explored with resin microspheres and resulted in decrease incidence of stasis as well as fluoroscopy time [129, 138]. No substantial difference between the oncological outcomes when using resin or glass microspheres for CLM have been shown [139].

^{166}Ho microspheres emit γ -radiation and are paramagnetic, thus they are getting increased attention due to facilitated imaging with MRI, enabling real-time infusion and tumor coverage monitoring [140]. In addition, ^{166}Ho microspheres scout dose is used for treatment planning, enabling more accurate prediction of intra- and extrahepatic distribution of radiation activity. The differences between the RE particles are summarized in the Table 4.

Although recent RCT failed to demonstrate the OS benefit of combination of RE with systemic chemotherapy compared with systemic chemotherapy alone in the first-line CLM treatment setting [141], subset of the patients with right-sided CRC showed OS advantage from this combinational treatment [142]. This is very important as the patients with right-sided CRC have less treatment options available than the left-sided CRC. Further investigation is of course needed to further assess this preliminary finding prior to its acceptance as a standard of care recommended in guidelines.

- TACE—The objective of TACE is to generate an hypoxic/ischemic environment as well as to synergistically induce chemotherapeutic tumor destruction. TACE showed promising results for patients progressing on irinotecan-based systemic chemotherapy. TACE is usually applied to treat unresectable CLM in chemorefractory setting [45]. The data on 2nd and 3rd line TACE is collected from RCT [106] as well as from observational studies demonstrating wide variation of response (35-85%) and median OS of 13.3-37 months [143], which compares favorably to other standard of care therapies for CLM.

DEBIRI-TACE [43] have been imposed as a novel drug-delivery vehicle allowing for higher concentrations of drugs (irinotecan) within the target tumor and lower systemic concentrations compared with conventional TACE (cTACE) [144]. cTACE is usually administered selectively/sub-selectively, whereas DEBIRI-TACE is commonly administered in the lobar fashion due to the fact, that irinotecan is a prodrug, activated by normal liver parenchyma, enabling to treat potentially occult liver lesions.

DEBIRI-TACE has been also explored for endovascular induction (neoadjuvant therapy) to target resectable CLM in PARAGON II study, with demonstrated low morbidity and 77% major response rate on pathology [145]. Radiopaque DC Bead LUMI™ beads (*BTG plc, United States*), loaded with irinotecan, are the first radiopaque beads, which have

been recently approved for CLM treatment, enabling to achieve much more precision for targeting, visualization of tumor coverage and defining the endpoints [146, 147].

To date, there is very limited evidence for bland embolization in CLM.

5. New IR treatments on the pipeline and possible molecular drivers

New IR treatments on the pipeline, including treatment of earlier stage metastatic disease, combinational LAT therapies, ablative dose RE as well as combination of immunotherapy and LAT are described in detail in Supplement 2.

Shift of the research scope in mCRC

At the time of OMD term introduction (2016), the main focus of IO/IR has been integration of new LATs, such as RFA, MWA, irreversible electroporation, RE and (chemo-) embolization, into mCRC treatment guidelines, improvement of techniques efficacy, identification of prognostic factors and multidisciplinary [45]. LAT were administered for OMD patients with curative or palliative intents [45].

However, since the year 2018, main research focus has been shifted to mCRC molecular determination, identification of the patients with curable OMD based on RNA analysis, exploration of tumor-stromal interaction as well as systemic effects following LAT and immunomodulation to induce abscopal effect (non-targeted tumor response) [148]. Also, mCRC OMD treatment concept has been modified, with recommendation to administer LAT with cytoreduction and curative intent to allow for “chance for cure” [148].

Identification of curable mCRC for better patient selection

It is crucial to be able to distinguish patients with potentially curable oligometastatic disease (OMD) from patients whose OMD is a part of a large cascade of widespread disease. This is very important as patients with new lesions following LAT of mCRC have been shown to have a poor prognosis. Prognostication strategies of CLM patients, based on RNA analysis, have been developed, identifying three distinct CLM similarity network fusion subtypes (SNFs) with unique patterns of mRNA and miRNA expression as well as with distinct histological and genetic features and prognosis, which could help to identify OMD patients with potentially curable disease [6]. Further investigation is needed to define to what extent these concepts apply to patients undergoing LAT and, more generally, to patients with more widespread disease.

Key mutations in LAT for mCRC

Most explored prognostic genetic signatures include in LAT for mCRC include KRAS and PI3K mutations. KRAS mutation was found to be an independent prognostic factor of poor outcomes following ⁹⁰Y RE [149, 150] and thermal ablation of CLM [10, 11, 151]. Concordant data indicate that a minimum ablation margin of > 10 mm is recommended when ablating KRAS mutant CLM [88] [151]. A minimal margin under 5 mm in KRAS mutant CLM carries 16.8 times the risk of local failure when compared to wild-type CLM

ablated with MM over 10 mm [88]. PI3K mutation was found to be associated with longer liver progression-free survival following ^{90}Y RE of CLM [114].

Artificial intelligence (AI) in IR

AI has the potential to improve mCRC patient outcomes following LAT by improving patient selection and response assessment via the identification of imaging features associated with oncological outcomes. Texture analysis has demonstrated its utility in the assessment of response to RE for CLM, allowing for the detection of disease progression, on average, 3.5 months before it was visible on RECIST 1.1 [152].

Also, AI has a potential to improve catheter navigation, ablation probe placement, imaging registration and estimation of ablation margins [153].

Conclusion

In conclusion, there is expanding evidence regarding the value of LAT to improve liver and overall progression-free survival in mCRC. Evidence regarding the effect of LAT on patient OS is lacking [21, 48]. At this time, prospective studies comparing different locoregional modalities or ablative modalities to surgery are limited and decision-making relies on limited data and a multidisciplinary decision making process. As IO techniques strive to take additional roles in the management of CLM, progress will ultimately be dependent on the ability to produce substantial prospective trial-based evidence.

6. Suggested readings

a. Cancer Societies:

- Society of Interventional Oncology (SIO): <http://www.sio-central.org/>
- Society of Interventional Radiology (SIR): <https://www.sirweb.org/>
- Society of Cardiovascular and Interventional Radiology of Europe (CIRSE): <https://www.cirse.org/>
- European Society of Oncologic Imaging (ESOI): <http://www.esoi-society.org/>
- European Organization for Research and Treatment of Cancer(EORTC): <http://www.eortc.org/>
- European Society for Medical Oncology (ESMO) : <https://www.esmo.org/>

b. Guidelines:

- European Society for Medical Oncology (ESMO) consensus guidelines for the management of patients with metastatic colorectal cancer [45];
- NCCN Clinical Practice Guidelines in Oncology for Colon Cancer [15];
- Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update [154];

- Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy [155];
- Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions [156];
- Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria Reporting Standards [157].

c. Publications:

- Ruers, T. *et al.* Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. *Journal of the National Cancer Institute* **109**, doi:[10.1093/jnci/djx015](https://doi.org/10.1093/jnci/djx015) (2017).
- Wasan, H. S. *et al.* First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. *The Lancet. Oncology* **18**, 1159-1171, doi:[10.1016/s1470-2045\(17\)30457-6](https://doi.org/10.1016/s1470-2045(17)30457-6) (2017).
- Pitroda, S. P. *et al.* Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. *Nature communications* **9**, 1793, doi:[10.1038/s41467-018-04278-6](https://doi.org/10.1038/s41467-018-04278-6) (2018).
- Shady, W., *et al.*, Percutaneous Microwave versus Radiofrequency Ablation of Colorectal Liver Metastases: Ablation with Clear Margins (A0) Provides the Best Local Tumor Control. *J Vasc Interv Radiol*, 2018. 29(2): p. 268-275.e1.
- Kurilova, I., *et al.*, Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases. *Clin Colorectal Cancer*, 2019. **18**(1): p. 8-18.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Funding

This study was not supported by any funding

References

1. National Cancer Institute Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Colon and Rectum Cancer <https://seer.cancer.gov/statfacts/html/colorect.html>. Accessed May 17, 2018.
2. Siegel RL, Miller KD, and Jemal A, Cancer statistics, 2018. *CA Cancer J Clin*, 2018. 68(1): p. 7–30. [PubMed: 29313949]
3. Ghiringhelli F, et al. , Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study. *Dig Liver Dis*, 2014. 46(9): p. 854–8. [PubMed: 24908575]
4. Tarraga Lopez PJ, Albero JS, and Rodriguez-Montes JA, Primary and secondary prevention of colorectal cancer. *Clin Med Insights Gastroenterol*, 2014. 7: p. 33–46. [PubMed: 25093007]

5. Lee MS, Menter DG, and Kopetz S, Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. *J Natl Compr Canc Netw*, 2017. 15(3): p. 411–419. [PubMed: 28275039]
6. Pitroda SP, et al. , Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. *Nat Commun*, 2018. 9(1): p. 1793. [PubMed: 29728604]
7. Pollock CB, et al. , Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. *Cancer Res*, 2005. 65(4): p. 1244–50. [PubMed: 15735008]
8. Tan C and Du X, KRAS mutation testing in metastatic colorectal cancer. *World J Gastroenterol*, 2012. 18(37): p. 5171–80. [PubMed: 23066310]
9. Brudvik KW, et al. , RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. *Ann Surg Oncol*, 2016. 23(8): p. 2635–43. [PubMed: 27016292]
10. Odisio BC, et al. , Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. *Br J Surg*, 2017. 104(6): p. 760–768. [PubMed: 28240361]
11. Shady W, et al. , Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. *Oncotarget*, 2017. 8(39): p. 66117–66127. [PubMed: 29029497]
12. Clarke CN and Kopetz ES, BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. *J Gastrointest Oncol*, 2015. 6(6): p. 660–7. [PubMed: 26697199]
13. Nojadeh JN, Behrouz Sharif S, and Sakhinia E, Microsatellite instability in colorectal cancer. *Excli j*, 2018. 17: p. 159–168. [PubMed: 29743854]
14. Creasy JM, et al. , Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? *Surgery*, 2018. 163(6): p. 1238–1244. [PubMed: 29455841]
15. Benson AB 3rd, et al. , Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*, 2017. 15(3): p. 370–398. [PubMed: 28275037]
16. Cameron J CA, *Current Surgical Therapy Philadelphia: Elsevier Health Sciences, E-Book 12th Edition*, 2016.
17. Adam R and Vinet E, Regional treatment of metastasis: surgery of colorectal liver metastases. *Ann Oncol*, 2004. 15 Suppl 4: p. iv103–6. [PubMed: 15477291]
18. Parkin DM, et al. , Global cancer statistics, 2002. *CA Cancer J Clin*, 2005. 55(2): p. 74–108. [PubMed: 15761078]
19. Kemeny NE, et al. , Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. *J Surg Oncol*, 2016. 113(5): p. 477–84. [PubMed: 26830685]
20. Fong Y, et al. , Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. *Ann Surg*, 1999. 230(3): p. 309–18; discussion 318–21. [PubMed: 10493478]
21. Ruers T, et al. , Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. *J Natl Cancer Inst*, 2017. 109(9).
22. Andre T, et al. , Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med*, 2004. 350(23): p. 2343–51. [PubMed: 15175436]
23. Kemeny N, et al. , Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. *N Engl J Med*, 1999. 341(27): p. 2039–48. [PubMed: 10615075]
24. Kemeny MM, et al. , Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. *J Clin Oncol*, 2002. 20(6): p. 1499–505. [PubMed: 11896097]
25. Lygidakis NJ, et al. , Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. *Hepatogastroenterology*, 2001. 48(42): p. 1685–91. [PubMed: 11813601]

26. Lorenz M, et al. , Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). *Ann Surg*, 1998. 228(6): p. 756–62. [PubMed: 9860474]
27. Kemeny N, et al. , Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. *J Surg Oncol*, 2005. 91(2): p. 97–101. [PubMed: 16028279]
28. Ducreux M, et al. , Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. *J Clin Oncol*, 2005. 23(22): p. 4881–7. [PubMed: 16009952]
29. Chen Y, et al. , Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer. *Onkologie*, 2012. 35(9): p. 480–4. [PubMed: 23007144]
30. Nordlinger B, et al. , Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. *Lancet*, 2008. 371(9617): p. 1007–16. [PubMed: 18358928]
31. Beppu T, et al. , FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases. *Anticancer Res*, 2010. 30(3): p. 1015–20. [PubMed: 20393029]
32. Uetake H, et al. , A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808). *Ann Surg Oncol*, 2015. 22(3): p. 908–15. [PubMed: 25465375]
33. Primrose J, et al. , Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. *Lancet Oncol*, 2014. 15(6): p. 601–11. [PubMed: 24717919]
34. Van Cutsem E, et al. , Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med*, 2009. 360(14): p. 1408–17. [PubMed: 19339720]
35. Bokemeyer C, et al. , Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol*, 2009. 27(5): p. 663–71. [PubMed: 19114683]
36. Falcone A, et al. , Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. *J Clin Oncol*, 2007. 25(13): p. 1670–6. [PubMed: 17470860]
37. Masi G, et al. , Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. *Ann Surg*, 2009. 249(3): p. 420–5. [PubMed: 19247029]
38. Cremolini C, et al. , Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. *Eur J Cancer*, 2017. 73: p. 74–84. [PubMed: 27986363]
39. Tomasello G, et al. , FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis. *JAMA Oncol*, 2017. 3(7): p. e170278. [PubMed: 28542671]
40. D'Angelica MI, et al. , Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. *Ann Surg*, 2015. 261(2): p. 353–60. [PubMed: 24646562]
41. Pak LM, et al. , Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. *J Surg Oncol*, 2018. 117(4): p. 634–643. [PubMed: 29165816]
42. Shah JL, et al. , Neoadjuvant transarterial radiation lobectomy for colorectal hepatic metastases: a small cohort analysis on safety, efficacy, and radiopathologic correlation. *J Gastrointest Oncol*, 2017. 8(3): p. E43–e51. [PubMed: 28736649]

43. Jones RP, et al. , Neoadjuvant treatment of colorectal liver metastases (CRLM) with drug eluting beads trans-arterial chemoembolization (DEBIRI-TACE): A multi-institute phase II study in resectable metastases. *Journal of Clinical Oncology*, 2012. 30(15_suppl): p. 3613–3613.
44. Livraghi T, et al. , Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the "test-of-time approach". *Cancer*, 2003. 97(12): p. 3027–35. [PubMed: 12784338]
45. Van Cutsem E, et al. , ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol*, 2016. 27(8): p. 1386–422. [PubMed: 27380959]
46. Maher B, et al. , The management of colorectal liver metastases. *Clin Radiol*, 2017. 72(8): p. 617–625. [PubMed: 28651746]
47. Gillams A, et al. , Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontieres meeting 2013. *Eur Radiol*, 2015. 25(12): p. 3438–54. [PubMed: 25994193]
48. Wasan HS, et al. , First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. *Lancet Oncol*, 2017. 18(9): p. 1159–1171. [PubMed: 28781171]
49. Yamakado K, et al. , Radiofrequency Ablation Combined with Hepatic Arterial Chemoembolization Using Degradable Starch Microsphere Mixed with Mitomycin C for the Treatment of Liver Metastasis from Colorectal Cancer: A Prospective Multicenter Study. *Cardiovasc Intervent Radiol*, 2017. 40(4): p. 560–567. [PubMed: 27999917]
50. Wu ZB, et al. , Percutaneous microwave ablation combined with synchronous transcatheter arterial chemoembolization for the treatment of colorectal liver metastases: results from a follow-up cohort. *Onco Targets Ther*, 2016. 9: p. 3783–9. [PubMed: 27382314]
51. Vogl TJ, et al. , Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation. *Eur J Radiol*, 2018. 102: p. 138–145. [PubMed: 29685527]
52. Ishikawa T, et al. , [Multiple liver metastases due to sigmoid colon cancer successfully treated by degradable starch microspheres (DSM)-TAE, radiofrequency ablation therapy, and Uzel/UFT]. *Gan To Kagaku Ryoho*, 2010. 37(2): p. 335–8. [PubMed: 20154497]
53. Fong ZV, et al. , Combined hepatic arterial embolization and hepatic ablation for unresectable colorectal metastases to the liver. *Am Surg*, 2012. 78(11): p. 1243–8. [PubMed: 23089443]
54. Wang DS, Louie JD, and Sze DY, Intra-arterial therapies for metastatic colorectal cancer. *Semin Intervent Radiol*, 2013. 30(1): p. 12–20. [PubMed: 24436513]
55. Gillams AR and Lees WR, Radio-frequency ablation of colorectal liver metastases in 167 patients. *Eur Radiol*, 2004. 14(12): p. 2261–7. [PubMed: 15599547]
56. Siperstein AE, et al. , Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. *Ann Surg*, 2007. 246(4): p. 559–65; discussion 565–7. [PubMed: 17893492]
57. Veltri A, et al. , Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. *Cardiovasc Intervent Radiol*, 2008. 31(5): p. 948–56. [PubMed: 18506519]
58. Gillams AR and Lees WR, Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. *Eur Radiol*, 2009. 19(5): p. 1206–13. [PubMed: 19137310]
59. Sofocleous CT, et al. , CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy. *J Vasc Interv Radiol*, 2011. 22(6): p. 755–61. [PubMed: 21514841]
60. Solbiati L, et al. , Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. *Radiology*, 2012. 265(3): p. 958–68. [PubMed: 23091175]
61. Shibata T, et al. , Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. *Cancer*, 2000. 89(2): p. 276–84. [PubMed: 10918156]
62. Tanaka K, et al. , Outcome after hepatic resection versus combined resection and microwave ablation for multiple bilobar colorectal metastases to the liver. *Surgery*, 2006. 139(2): p. 263–73. [PubMed: 16455336]

63. Shady W, et al. , Percutaneous Microwave versus Radiofrequency Ablation of Colorectal Liver Metastases: Ablation with Clear Margins (A0) Provides the Best Local Tumor Control. *J Vasc Interv Radiol*, 2018. 29(2): p. 268–275.e1. [PubMed: 29203394]
64. Liang P, et al. , Prognostic factors for percutaneous microwave coagulation therapy of hepatic metastases. *AJR Am J Roentgenol*, 2003. 181(5): p. 1319–25. [PubMed: 14573427]
65. Shyn PB, et al. , Percutaneous imaging-guided cryoablation of liver tumors: predicting local progression on 24-hour MRI. *AJR Am J Roentgenol*, 2014. 203(2): p. W181–91. [PubMed: 24555531]
66. Vogl TJ, et al. , Thermal ablation of liver metastases from colorectal cancer: radiofrequency, microwave and laser ablation therapies. *Radiol Med*, 2014. 119(7): p. 451–61. [PubMed: 24894923]
67. Sartori S, et al. , Laser ablation of liver tumors: An ancillary technique, or an alternative to radiofrequency and microwave? *World J Radiol*, 2017. 9(3): p. 91–96. [PubMed: 28396723]
68. Sartori S, Tombesi P, and Di Vece F, Thermal ablation in colorectal liver metastases: Lack of evidence or lack of capability to prove the evidence? *World J Gastroenterol*, 2016. 22(13): p. 3511–5. [PubMed: 27053843]
69. Park MY, et al. , Preliminary experience using high intensity focused ultrasound for treating liver metastasis from colon and stomach cancer. *Int J Hyperthermia*, 2009. 25(3): p. 180–8. [PubMed: 19212862]
70. Lyu T, et al. , Irreversible electroporation in primary and metastatic hepatic malignancies: A review. *Medicine (Baltimore)*, 2017. 96(17): p. e6386. [PubMed: 28445252]
71. Scheffer HJ, et al. , Irreversible Electroporation for Colorectal Liver Metastases. *Tech Vasc Interv Radiol*, 2015. 18(3): p. 159–69. [PubMed: 26365546]
72. Schoellhammer HF, et al. , Colorectal liver metastases: making the unresectable resectable using irreversible electroporation for microscopic positive margins - a case report. *BMC Cancer*, 2015. 15: p. 271. [PubMed: 25886376]
73. Weng M, et al. , Radiofrequency ablation versus resection for colorectal cancer liver metastases: a meta-analysis. *PLoS One*, 2012. 7(9): p. e45493. [PubMed: 23029051]
74. Mulier S, et al. , Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? An update. *Dig Surg*, 2008. 25(6): p. 445–60. [PubMed: 19212117]
75. Pathak S, et al. , Ablative therapies for colorectal liver metastases: a systematic review. *Colorectal Dis*, 2011. 13(9): p. e252–65. [PubMed: 21689362]
76. Ruers T, et al. , Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). *Ann Oncol*, 2012. 23(10): p. 2619–26. [PubMed: 22431703]
77. Petre EN, et al. , Treatment of pulmonary colorectal metastases by radiofrequency ablation. *Clin Colorectal Cancer*, 2013. 12(1): p. 37–44. [PubMed: 23026111]
78. Mouli SK, et al. , The Role of Percutaneous Image-Guided Thermal Ablation for the Treatment of Pulmonary Malignancies. *AJR Am J Roentgenol*, 2017. 209(4): p. 740–751. [PubMed: 28657845]
79. Bruix J and Sherman M, Management of hepatocellular carcinoma. *Hepatology*, 2005. 42(5): p. 1208–36. [PubMed: 16250051]
80. Kudo M and Okanoue T, Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. *Oncology*, 2007. 72 Suppl 1: p. 2–15.
81. Omata M, et al. , Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. *Hepatol Int*, 2010. 4(2): p. 439–74. [PubMed: 20827404]
82. Ayav A, et al. , Radiofrequency ablation of unresectable liver tumors: factors associated with incomplete ablation or local recurrence. *Am J Surg*, 2010. 200(4): p. 435–9. [PubMed: 20409524]
83. Amersi FF, et al. , Long-term survival after radiofrequency ablation of complex unresectable liver tumors. *Arch Surg*, 2006. 141(6): p. 581–7; discussion 587-8. [PubMed: 16785359]

84. Veenendaal LM, Borel Rinkes IH, and van Hillegersberg R, Multipolar radiofrequency ablation of large hepatic metastases of endocrine tumours. *Eur J Gastroenterol Hepatol*, 2006. 18(1): p. 89–92. [PubMed: 16357626]
85. Hur H, et al. , Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. *Am J Surg*, 2009. 197(6): p. 728–36. [PubMed: 18789428]
86. Shady W, et al. , Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center. *Radiology*, 2016. 278(2): p. 601–11. [PubMed: 26267832]
87. Kim YS, et al. , Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. *Eur J Radiol*, 2006. 59(3): p. 432–41. [PubMed: 16690240]
88. Mulier S, et al. , Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. *Ann Surg*, 2005. 242(2): p. 158–71. [PubMed: 16041205]
89. Lee WS, et al. , Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. *J Clin Gastroenterol*, 2008. 42(8): p. 945–9. [PubMed: 18438208]
90. Van Tilborg AA, et al. , Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. *Br J Radiol*, 2011. 84(1002): p. 556–65. [PubMed: 21159807]
91. Berber E, Pelley R, and Siperstein AE, Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. *J Clin Oncol*, 2005. 23(7): p. 1358–64. [PubMed: 15684312]
92. Abdalla EK, et al. , Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. *Ann Surg*, 2004. 239(6): p. 818–25; discussion 825–7. [PubMed: 15166961]
93. Wang X, et al. , Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. *Cardiovasc Intervent Radiol*, 2013. 36(1): p. 166–75. [PubMed: 22535243]
94. Ryan ER, et al. , Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. *Radiology*, 2013. 268(1): p. 288–95. [PubMed: 23564714]
95. Sofocleous CT, et al. , Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. *Radiology*, 2008. 249(1): p. 364–74. [PubMed: 18796687]
96. Sotirchos VS, et al. , Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can Be Used to Predict Oncologic Outcome. *Radiology*, 2016. 280(3): p. 949–59. [PubMed: 27010254]
97. Puijk RS, et al. , Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. *BMC Cancer*, 2018. 18(1): p. 821. [PubMed: 30111304]
98. Correa-Gallego C, et al. , A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases. *Ann Surg Oncol*, 2014. 21(13): p. 4278–83. [PubMed: 24889486]
99. Qian GJ, et al. , Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: experimental and clinical studies. *Eur Radiol*, 2012. 22(9): p. 1983–90. [PubMed: 22544225]
100. Di Vece F, et al. , Coagulation areas produced by cool-tip radiofrequency ablation and microwave ablation using a device to decrease back-heating effects: a prospective pilot study. *Cardiovasc Intervent Radiol*, 2014. 37(3): p. 723–9. [PubMed: 24196263]
101. Cavagnaro M, et al. , A minimally invasive antenna for microwave ablation therapies: design, performances, and experimental assessment. *IEEE Trans Biomed Eng*, 2011. 58(4): p. 949–59. [PubMed: 21172749]

102. Sag AA, Selcukbiricik F, and Mandel NM, Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. *World J Gastroenterol*, 2016. 22(11): p. 3127–49. [PubMed: 27003990]
103. Aliberti C, et al. , Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead(R), drug-eluting bead loaded with irinotecan: results of a phase II clinical study. *Anticancer Res*, 2011. 31(12): p. 4581–7. [PubMed: 22199334]
104. Martin RC, et al. , Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. *Ann Surg Oncol*, 2011. 18(1): p. 192–8. [PubMed: 20740319]
105. Iezzi R, et al. , Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study. *Cardiovasc Intervent Radiol*, 2015. 38(6): p. 1523–31. [PubMed: 25799948]
106. Fiorentini G, et al. , Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. *Anticancer Res*, 2012. 32(4): p. 1387–95. [PubMed: 22493375]
107. Albert M, et al. , Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. *Cancer*, 2011. 117(2): p. 343–52. [PubMed: 20830766]
108. Vogl TJ, et al. , Regional chemotherapy of the lung: transpulmonary chemoembolization in malignant lung tumors. *Semin Intervent Radiol*, 2013. 30(2): p. 176–84. [PubMed: 24436534]
109. Sofocleous CT, et al. , Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes. *Clin Colorectal Cancer*, 2015. 14(4): p. 296–305. [PubMed: 26277696]
110. Shady W, et al. , Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0. *Eur J Radiol*, 2016. 85(6): p. 1224–31. [PubMed: 27161074]
111. Boas FE, Bodei L, and Sofocleous CT, Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes. *J Nucl Med*, 2017. 58(Suppl 2): p. 104s–111s. [PubMed: 28864605]
112. Sofocleous CT, et al. , Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. *Clin Colorectal Cancer*, 2014. 13(1): p. 27–36. [PubMed: 24370352]
113. Sotirchos VS, et al. , Safe and Successful Yttrium-90 Resin Microsphere Radioembolization in a Heavily Pretreated Patient with Chemorefractory Colorectal Liver Metastases after Biliary Stent Placement above the Papilla. *Case Reports Hepatol*, 2014. 2014: p. 921406. [PubMed: 25580316]
114. Ziv E, et al. , PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases. *Oncotarget*, 2017. 8(14): p. 23529–23538. [PubMed: 28206962]
115. Braat A, et al. , Adequate SIRT activity dose is as important as adequate chemotherapy dose. *Lancet Oncol*, 2017. 18(11): p. e636. [PubMed: 29208390]
116. Dutton SJ, et al. , FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. *BMC Cancer*, 2014. 14: p. 497. [PubMed: 25011439]
117. Gibbs P, et al. , Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRCFOX study. *BMC Cancer*, 2014. 14: p. 897. [PubMed: 25487708]
118. Khajornjiraphan N, Thu NA, and Chow PK, Yttrium-90 microspheres: a review of its emerging clinical indications. *Liver Cancer*, 2015. 4(1): p. 6–15. [PubMed: 26020025]
119. Murray D and McEwan AJ, Radiobiology of systemic radiation therapy. *Cancer Biother Radiopharm*, 2007. 22(1): p. 1–23. [PubMed: 17627411]

120. Campbell AM, Bailey IH, and Burton MA, Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. *Phys Med Biol*, 2000. 45(4): p. 1023–33. [PubMed: 10795989]
121. Kennedy A, et al. , Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. *Int J Radiat Oncol Biol Phys*, 2007. 68(1): p. 13–23. [PubMed: 17448867]
122. Hendlisz A, et al. , Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. *J Clin Oncol*, 2010. 28(23): p. 3687–94. [PubMed: 20567019]
123. Van Hazel G, et al. , Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. *J Surg Oncol*, 2004. 88(2): p. 78–85. [PubMed: 15499601]
124. Gray B, et al. , Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. *Ann Oncol*, 2001. 12(12): p. 1711–20. [PubMed: 11843249]
125. Kennedy AS, et al. , Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. *Int J Radiat Oncol Biol Phys*, 2004. 60(5): p. 1552–63. [PubMed: 15590187]
126. Sharma RA, et al. , Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. *J Clin Oncol*, 2007. 25(9): p. 1099–106. [PubMed: 17369573]
127. Vente MA, et al. , Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. *Eur Radiol*, 2009. 19(4): p. 951–9. [PubMed: 18989675]
128. Cosimelli M, et al. , Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. *Br J Cancer*, 2010. 103(3): p. 324–31. [PubMed: 20628388]
129. Kurilova I, et al. , (90)Y Resin Microspheres Radioembolization for Colon Cancer Liver Metastases Using Full-Strength Contrast Material. *Cardiovasc Intervent Radiol*, 2018.
130. Puippe G, Pfammatter T, and Schaefer N, Arterial Therapies of Non-Colorectal Liver Metastases. *Viszeralmedizin*, 2015. 31(6): p. 414–22. [PubMed: 26889145]
131. Fan KY, et al. , Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. *Contemp Clin Trials*, 2016. 50: p. 143–9. [PubMed: 27520932]
132. Gordon AC, Salem R, and Lewandowski RJ, Yttrium-90 Radioembolization for Breast Cancer Liver Metastases. *J Vasc Interv Radiol*, 2016. 27(9): p. 1316–1319. [PubMed: 27566423]
133. Bester L, et al. , Radioembolisation with Yttrium-90 microspheres: an effective treatment modality for unresectable liver metastases. *J Med Imaging Radiat Oncol*, 2013. 57(1): p. 72–80. [PubMed: 23374558]
134. Seidensticker R, et al. , Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. *Cardiovasc Intervent Radiol*, 2012. 35(5): p. 1066–73. [PubMed: 21800231]
135. Burrill J, H. U, Liu DM, Advances in radioembolization - Embolics and isotopes. *Nuclear Medi Radiat Ther*, (2011;2:107).
136. Piana PM, et al. , Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes. *HPB (Oxford)*, 2014. 16(4): p. 336–41. [PubMed: 23782387]
137. Murthy R, et al. , Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. *J Vasc Interv Radiol*, 2005. 16(7): p. 937–45. [PubMed: 16002501]
138. Chao C, et al. , Effect of Substituting 50% Isovue for Sterile Water as the Delivery Medium for SIR-Spheres: Improved Dose Delivery and Decreased Incidence of Stasis. *Clin Nucl Med*, 2017. 42(3): p. 176–179. [PubMed: 28072623]

139. Kurilova I, et al. , Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases. *Clin Colorectal Cancer*, 2019. 18(1): p. 8–18. [PubMed: 30297264]
140. Prince JF, et al. , Efficacy of Radioembolization with (166)Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study. *J Nucl Med*, 2018. 59(4): p. 582–588. [PubMed: 28916623]
141. van Hazel GA, et al. , SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. *J Clin Oncol*, 2016. 34(15): p. 1723–31. [PubMed: 26903575]
142. Gibbs P, et al. , Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. *Clin Colorectal Cancer*, 2018. 17(4): p. e617–e629. [PubMed: 30033117]
143. Richardson AJ, Laurence JM, and Lam VW, Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. *J Vasc Interv Radiol*, 2013. 24(8): p. 1209–17. [PubMed: 23885916]
144. Song JE and Kim DY, Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. *World J Hepatol*, 2017. 9(18): p. 808–814. [PubMed: 28706579]
145. Jones RP, et al. , PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. *Eur J Surg Oncol*, 2016. 42(12): p. 1866–1872. [PubMed: 27561844]
146. Levy EB, et al. , First Human Experience with Directly Image-able Iodinated Embolization Microbeads. *Cardiovasc Intervent Radiol*, 2016. 39(8): p. 1177–86. [PubMed: 27206503]
147. Caine M, et al. , Comparison of microsphere penetration with LC Bead LUMI versus other commercial microspheres. *J Mech Behav Biomed Mater*, 2018. 78: p. 46–55. [PubMed: 29132100]
148. Yoshino T, et al. , Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. *Ann Oncol*, 2018. 29(1): p. 44–70. [PubMed: 29155929]
149. Lahti SJ, et al. , KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases. *J Vasc Interv Radiol*, 2015. 26(8): p. 1102–11. [PubMed: 26210240]
150. Janowski E, et al. , Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies. *Oncol Rep*, 2017. 37(1): p. 57–65. [PubMed: 28004119]
151. Calandri M, et al. , Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. *Eur Radiol*, 2018. 28(7): p. 2727–2734. [PubMed: 29417253]
152. Reimer RP, Reimer P, and Mahnken AH, Assessment of Therapy Response to Transarterial Radioembolization for Liver Metastases by Means of Post-treatment MRI-Based Texture Analysis. *Cardiovasc Intervent Radiol*, 2018.
153. Letzen B, Wang CJ, and Chapiro J, The Role of Artificial Intelligence in Interventional Oncology: A Primer. *J Vasc Interv Radiol*, 2019. 30(1): p. 38–41.e1. [PubMed: 30528289]
154. Ahmed M, et al. , Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. *Radiology*, 2014. 273(1): p. 241–60. [PubMed: 24927329]
155. Gaba RC, et al. , Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. *J Vasc Interv Radiol*, 2017. 28(9): p. 1210–1223.e3. [PubMed: 28669744]
156. Padia SA, et al. , Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. *J Vasc Interv Radiol*, 2017. 28(1): p. 1–15. [PubMed: 27836405]
157. Gaba RC, et al. , Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. *J Vasc Interv Radiol*, 2016. 27(4): p. 457–73. [PubMed: 26851158]

158. Bipat S, et al. , Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis. *Radiology*, 2005. 237(1): p. 123–31. [PubMed: 16100087]
159. Floriani I, et al. , Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. *J Magn Reson Imaging*, 2010. 31(1): p. 19–31. [PubMed: 20027569]
160. Kulemann V, et al. , Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? *Eur J Radiol*, 2011. 79(2): p. e1–6. [PubMed: 20392584]
161. Yoo HJ, Lee JS, and Lee JM, Integrated whole body MR/PET: where are we? *Korean J Radiol*, 2015. 16(1): p. 32–49. [PubMed: 25598673]
162. Dietrich CF, et al. , Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. *World J Gastroenterol*, 2006. 12(11): p. 1699–705. [PubMed: 16586537]
163. Tournigand C, et al. , FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol*, 2004. 22(2): p. 229–37. [PubMed: 14657227]
164. Venook AP, et al. , Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. *Jama*, 2017. 317(23): p. 2392–2401. [PubMed: 28632865]
165. Venook AP, N. D, Innocenti F, et al. , Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). *J Clin Oncol* 34, 2016 (suppl; abstr 3504), 2016.
166. Hecht JR, et al. , A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. *J Clin Oncol*, 2009. 27(5): p. 672–80. [PubMed: 19114685]
167. Tol J, et al. , A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. *Ann Oncol*, 2008. 19(4): p. 734–8. [PubMed: 18272912]
168. Douillard JY, et al. , Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol*, 2010. 28(31): p. 4697–705. [PubMed: 20921465]
169. Peeters M, et al. , Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. *J Clin Oncol*, 2010. 28(31): p. 4706–13. [PubMed: 20921462]
170. Yamada Y, et al. , Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. *Lancet Oncol*, 2013. 14(13): p. 1278–86. [PubMed: 24225157]
171. Muro K, et al. , Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). *Lancet Oncol*, 2010. 11(9): p. 853–60. [PubMed: 20708966]
172. Van Cutsem E, et al. , Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. *Target Oncol*, 2016. 11(3): p. 383–400. [PubMed: 26706237]
173. Folprecht G, et al. , Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. *Ann Oncol*, 2016. 27(7): p. 1273–9. [PubMed: 27091810]
174. Tabernero J, et al. , Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy

- with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. *Lancet Oncol*, 2015. 16(5): p. 499–508. [PubMed: 25877855]
175. Grothey A, et al. , Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet*, 2013. 381(9863): p. 303–12. [PubMed: 23177514]
 176. Mayer RJ, et al. , Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Engl J Med*, 2015. 372(20): p. 1909–19. [PubMed: 25970050]
 177. Cercek A, et al. , Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. *J Surg Oncol*, 2016. 114(6): p. 655–663. [PubMed: 27566258]
 178. Le DT, et al. , PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med*, 2015. 372(26): p. 2509–20. [PubMed: 26028255]
 179. Le DT UJ, Wang H, et al. , Programmed death-1 blockade in mismatch repair deficient colorectal cancer (abstract). *J Clin oncol* 34, 2016 (suppl; abstr 103) 2016. [PubMed: 26628472]
 180. Overman MJ, K.S., McDermott RS, et al. , Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results (abstract). *J Clin Oncol* 34, 2016 (suppl; abstr 3501), 2016.
 181. Kemeny NE and Gonen M, Hepatic arterial infusion after liver resection. *N Engl J Med*, 2005. 352(7): p. 734–5. [PubMed: 15716576]
 182. Clavien PA, et al. , Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. *Surgery*, 2002. 131(4): p. 433–42. [PubMed: 11935134]
 183. Kemeny N, et al. , Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. *J Clin Oncol*, 2005. 23(22): p. 4888–96. [PubMed: 16009951]
 184. Kemeny NE, et al. , Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. *J Clin Oncol*, 2009. 27(21): p. 3465–71. [PubMed: 19470932]
 185. Gallagher DJ, et al. , Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. *Ann Oncol*, 2007. 18(12): p. 1995–9. [PubMed: 17962209]
 186. Goere D, et al. , Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. *Ann Surg*, 2010. 251(4): p. 686–91. [PubMed: 20224373]
 187. Levi FA, et al. , Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. *Ann Oncol*, 2016. 27(2): p. 267–74. [PubMed: 26578731]
 188. Cercek A, et al. , Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. *Ann Surg Oncol*, 2014. 21(2): p. 479–86. [PubMed: 24154839]
 189. Xu C, et al. , Radiofrequency Ablation for Liver Metastases after Transarterial Chemoembolization: A Systemic Analysis. *Asian Pac J Cancer Prev*, 2015. 16(12): p. 5101–6. [PubMed: 26163649]
 190. Bloomston M, et al. , Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. *Am Surg*, 2002. 68(9): p. 827–31. [PubMed: 12356160]
 191. Meiers C, et al. , Safety and initial efficacy of radiation segmentectomy for the treatment of hepatic metastases. *J Gastrointest Oncol*, 2018. 9(2): p. 311–315. [PubMed: 29755770]
 192. Vouche M, et al. , Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. *Hepatology*, 2014. 60(1): p. 192–201. [PubMed: 24691943]
 193. Teo JY, et al. , A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. *HPB (Oxford)*, 2016. 18(1): p. 7–12. [PubMed: 26776845]

194. Fernandez-Ros N, et al. , Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. *HPB (Oxford)*, 2014. 16(3): p. 243–9. [PubMed: 23530966]
195. Marabelle A, et al. , Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). *Ann Oncol*, 2018. 29(11): p. 2163–2174. [PubMed: 30295695]
196. Broughton G 2nd, Janis JE, and Attinger CE, Wound healing: an overview. *Plast Reconstr Surg*, 2006. 117(7 Suppl): p. 1e-S–32e-S. [PubMed: 16404237]
197. Li LY, et al. , Prospective comparison of five mediators of the systemic response after high-intensity focused ultrasound and targeted cryoablation for localized prostate cancer. *BJU Int*, 2009. 104(8): p. 1063–7. [PubMed: 19298406]
198. Schell SR, et al. , Pro- and antiinflammatory cytokine production after radiofrequency ablation of unresectable hepatic tumors. *J Am Coll Surg*, 2002. 195(6): p. 774–81. [PubMed: 12495309]
199. de Jong KP, et al. , Serum response of hepatocyte growth factor, insulin-like growth factor-I, interleukin-6, and acute phase proteins in patients with colorectal liver metastases treated with partial hepatectomy or cryosurgery. *J Hepatol*, 2001. 34(3): p. 422–7. [PubMed: 11322204]
200. Erinjeri JP, et al. , Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10. *J Vasc Interv Radiol*, 2013. 24(8): p. 1105–12. [PubMed: 23582441]
201. Takahashi Y, et al. , Immunological effect of local ablation combined with immunotherapy on solid malignancies. *Chin J Cancer*, 2017. 36(1): p. 49. [PubMed: 28592286]
202. Slovak R, et al. , Immuno-thermal ablations - boosting the anticancer immune response. *J Immunother Cancer*, 2017. 5(1): p. 78. [PubMed: 29037259]
203. Lemdani K, et al. , Improvement of immune response after radiofrequency ablation in colorectal cancer. *Journal of Clinical Oncology*, 2018. 36(5_suppl): p. 102–102.
204. Katz SC, et al. , Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases. *Clin Cancer Res*, 2015. 21(14): p. 3149–59. [PubMed: 25850950]
205. Fong Y, et al. , A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. *Mol Ther*, 2009. 17(2): p. 389–94. [PubMed: 19018254]
206. Mehta A, Oklu R, and Sheth RA, Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response? *Gastroenterol Res Pract*, 2016. 2016: p. 9251375. [PubMed: 27051417]
207. Haen SP, et al. , More than just tumor destruction: immunomodulation by thermal ablation of cancer. *Clin Dev Immunol*, 2011. 2011: p. 160250. [PubMed: 22242035]
208. Fagnoni FF, et al. , Combination of radiofrequency ablation and immunotherapy. *Front Biosci*, 2008. 13: p. 369–81. [PubMed: 17981554]
209. den Brok MH, et al. , Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction. *Vaccine*, 2012. 30(4): p. 737–44. [PubMed: 22138178]
210. den Brok MH, et al. , Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation. *Nat Commun*, 2016. 7: p. 13324. [PubMed: 27819292]
211. van den Bijgaart RJ, et al. , Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. *Cancer Immunol Immunother*, 2017. 66(2): p. 247–258. [PubMed: 27585790]
212. Nierkens S, et al. , In vivo colocalization of antigen and CpG [corrected] within dendritic cells is associated with the efficacy of cancer immunotherapy. *Cancer Res*, 2008. 68(13): p. 5390–6. [PubMed: 18593941]
213. Grivennikov SI, Greten FR, and Karin M, Immunity, inflammation, and cancer. *Cell*, 2010. 140(6): p. 883–99. [PubMed: 20303878]
214. Trikha M, et al. , Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. *Clin Cancer Res*, 2003. 9(13): p. 4653–65. [PubMed: 14581334]

Table 1.

Liver-directed therapies for colorectal cancer liver metastases.

Liver-Directed therapies for colorectal cancer liver metastases		
10 most important points of the cancer	1	Colorectal cancer (CRC) is the third most common cancer worldwide. Liver is the most common metastatic site, with synchronous metastasis being an independent poor prognostic factor [3].
	2	Genetic molecular profiles not only have impact on prognosis, but also provide therapeutic values. KRAS mutation is detected in 35-45% of CRCs and it is a strong negative <i>prognostic</i> biomarker and <i>predictive</i> biomarker. BRAF-mutant cancers comprise 10% of all CRCs and associated with poorer overall survival.
	3	Systemic chemotherapies are proven to have survival benefit in all clinical settings from post liver metastectomy, to converting unresectable liver metastasis to resectable, to maintaining quality of life.
	4	Cytotoxic chemotherapies remain the mainstream therapy for metastatic CRC, even in patients with resectable or amenable to ablation disease. Chemotherapy combined with resection or ablation of all metastatic sites significantly improve outcomes in this patient population [21].
	5	Treatment options for liver-only or dominant metastasis include surgical resection/ablation, loco-regional debulking interventions, systemic cytotoxic chemotherapy, intra-arterial pump chemotherapy, biological therapy as well as immunotherapy, with immune checkpoint inhibitors benefiting small percentage of patients whose tumor is MMR deficient.
	6	When liver metastases are completely resected and/or ablated, long-term survival and potential cure could be achieved. Clinical Risk Score (CRS) and margins impact surgical outcomes and potential for cure [14, 20].
	7	Despite a relevantly high recurrence rate following resection and or ablation of liver metastases, ablation (with or without resection) of CLM in addition to chemotherapy prolongs patient survival [21]. Modified CRS impacts outcomes of ablation similarly to surgery. Ablation with margins over 10 mm offers the best local tumor control [63, 86, 96].
	8	Intra-arterial therapies and in particular Y-90 radioembolization is recommended for CLM treatment in the salvage setting with liver disease progression while on or after second line chemotherapy with encouraging oncologic outcomes [139].
	9	Liver-directed chemotherapy through hepatic arterial pump demonstrated survival benefit in multiple clinical settings including adjuvant, neoadjuvant and metastatic.
	10	Loco-regional interventions are also being combined with different systemic therapies to enhance anti-tumor effect and to facilitate drug delivery.
5 most important numbers of the cancer	1	There are estimated 140,250 new cases of CRC, and 50,630 patients will die from CRC in 2018 in the USA.
	2	15% patients present with synchronous liver metastases, 50% patients with CRC will ultimately develop liver metastasis.
	3	Only around 15-20% of the patients with CLM are eligible for liver resection.
	4	The recurrence rate following resection of liver metastases from CRC is in the order of 60–70%.
	5	Up to 38% patients with initially unresectable liver metastases could have disease converted to surgically resectable after receiving proper therapy.
3 major pivotal studies for the last 5 years	1	Ruers, T. <i>et al.</i> Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. <i>Journal of the National Cancer Institute</i> 109 ,doi: 10.1093/jnci/djx015 (2017). added
	2	Groot Koerkamp B, Sadot E, Kemeny NE, et al. Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis of 2,368 consecutive patients. <i>J Clin Oncol.</i> 2017;35:1938–1944.
	3	Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>The Lancet Oncology.</i> 2017;18(9):1159-71
2 messages about the cancer	1	All metastatic colorectal cancer with liver metastasis should be managed by multidisciplinary teams including medical oncologist, surgical oncologist, interventional radiologist as well as diagnostic radiologist.
	2	All patients should be considered for clinical trials.

Liver-Directed therapies for colorectal cancer liver metastases	
1 prediction for the 5 future years	Combination of loco-regional plus systemic therapies might be the leading approach in this patient population in an effort to prolong overall survival.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2.

Imaging modalities used for colorectal liver metastases (CLM) detection and follow-up.

Nr.	Imaging modality	Description
1.	CT of the chest/ abdomen/ pelvis with triphasic liver protocol	It is the most commonly used imaging modality in diagnosis of both intrahepatic and extrahepatic metastases as well as post-treatment follow-up [158-160]; however, CT is not sensitive enough to detect lesions smaller than 1 cm.
2.	MRI with liver-specific contrast agents and diffusion-weighted imaging	It is more sensitive than CT for detecting smaller CLM, it is more often chosen by surgeons when planning metastatectomy [158-160].
3.	¹⁸ F-FDG PET/CT imaging	It is not routinely used in CRC work-up, however, if CT or MRI detects suspicious but inconclusive abnormalities, ¹⁸ F-FDG PET/CT may be considered. It is recommended for restaging prior to resection or ablation of metastatic disease.
4.	¹⁸ F FDG PET/MRI imaging	It is gaining some popularity for its sensitivity and specificity in diagnosing CLMs [161], however it is not available in many institutions;
5.	Traditional ultrasound (US), contrast-enhanced ultrasound (CEUS), and intra-operative US	They all have a role in detecting CLM [162], especially useful for image-guided needle biopsy of CLM.

TABLE 3.

Palliative treatment options for the patients with colorectal liver metastases, adopted from several current guidelines.

Treatment regimen	Description
First line systemic palliative chemotherapy options	
FOLFOX and FOLFIRI +/- bevacizumab or cetuximab [163, 164]	<ul style="list-style-type: none"> Left-sided wild-type KRAS colorectal cancer (CRC) patients have significant survival benefit from cetuximab, while right-sided CRC patients have survival benefit from bevacizumab [165]. Combining both anti-VEGF and anti-EGFR agents is not recommended due to poorer outcome [166, 167].
FOLFOX or FOLFIRI + panitumumab	For the patients with RAS wild-type tumor [168, 169].
S-1 plus oxaliplatin or irinotecan	S-1 is only used in selected countries, such as Japan and Korea [170, 171].
FOLFIRINOX or FOLFOXIRI	This regimen is used only in selected younger patients with high tumor burden and RAS or BRAF mutation.
HAI with FUDR or in combination with FU/LV, FOLFOX or FOLFIRI	For patients with unresectable liver metastasis [40, 41].
Beyond first line systemic chemotherapy options	
Irinotecan-based chemotherapy	<p>For patients received oxaliplatin based initial therapy, irinotecan-based chemotherapy is considered to be the next treatment choice.</p> <p>The following regimens are recommended:</p> <ul style="list-style-type: none"> FOLFIRI; FOLFIRI + bevacizumab (for patients with tumor bearing RAS mutation); FOLFIRI + cetuximab/ panitumumab (for patients with RAS wild-type tumor); FOLFIRI with intravenous aflibercept [172, 173]; FOLFIRI with ramucirumab [174].
Oxaliplatin-based chemotherapy	<ul style="list-style-type: none"> For patients received irinotecan-based initial therapy, changing to oxaliplatin-based chemotherapy with or without biological agents depending on RAS mutational status would be reasonable. For RAS wild-type, anti-EGFR therapy would be appropriate, anti-VEGF agent can be also be considered, although only anti-VEGF agent would be indicated if RAS mutations present.
Regorafenib or trifluridine-tipiracil	For the patients who have received and failed both oxaliplatin- and irinotecan-based be offered for additional therapy based on performance status and organ functions, we suggest single agent regorafenib or trifluridine-tipiracil [175] [176].
HAI therapy	HAI therapy remains effective treatment for patients who had prior systemic chemotherapy exposure [40, 41, 177].
Immunotherapy (in selective patients)	<ul style="list-style-type: none"> Mismatch repair protein (MMR) deficient or MSI-high tumors may benefit from check point inhibitors. Patients with MMR-deficient metastatic CRC had a 50% objective response rate (ORR) and a 89% disease control rate (DCR) when treated with pembrolizumab, while in contrast, the ORR and DCR were 0 and 16% respectively in MMR-proficient mCRC [178, 179]. Similar results were also seen in CheckMate-142, in which patients received nivolumab with or without ipilimumab. Significantly higher ORR and PFS were demonstrated in MMR-deficient mCRC [180].
Reutilizing the regimen initially used in the treatment sequence	During the often lengthy phase of sequential therapy, tumors may regain sensitivity to the previously used agents.

Treatment regimen	Description
Locoregional treatment options	
HAI therapy	For liver-dominant metastatic CRC (early stage multifocal liver-only disease)
Transarterial chemoembolization or radioembolization	For liver-dominant metastatic CRC (late stages multifocal liver-only disease)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

TABLE 4.Comparison of ^{90}Y (resin and glass-based) and ^{166}Ho microspheres for radioembolization

	SIR-Spheres™	Therasphere™	QuiremSpheres™
Matrix	Resin	Glass	PLLA
Diameter	20-60µm (mean 32 µm)	25 µm	30 µm
Isotope	Yttrium-90		Holmium-166
T 1/2	64.5 hours		26.8 hours
Density	1.6 g/cm ³	3.4 g/cm ³	1.4 g/cm ³
Number of spheres	33-50 mln	4 mln	33 mln
Amount per dose	900-1370 mg	110 mg	600 mg
Activity per sphere	50 Bq	1250-2500 Bq	200-400 Bq
Activity per dose	2-3 GBq	5-15 GBq	6-12 GBq
Imaging	Y-90 PET or Bremsstrahlung SPECT/CT		SPECT/MRI/CT
Test dose	99m Tc-MAA		Ho-spheres/Tc-MAA
Company	Sirtex Medical Limited, NSW, Australia	BTG, London, UK	Terumo, Nijmegen, NL
Year of creation	1974	1989	1994
CE trade mark	2002	1999	2014
FDA indications	Unresectable colorectal liver metastases in combination with intrahepatic floxuridine	Humanitarian device exemption for unresectable HCC	Unresectable colorectal liver metastases
Activity calculation	BSA, partition model	MIRD-based approach	Two-compartment-based dosimetry